OncoMatch/Clinical Trials/NCT06122584
Diagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients With Newly-Diagnosed Prostate Cancer
Is NCT06122584 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies [18F]PSMA-1007 for prostate cancer.
Treatment: [18F]PSMA-1007 — This study assess the Diagnostic Performance of \[18F\]PSMA-1007 PET/CT Imaging in Patients with Newly-Diagnosed High-Risk or Very-High-Risk Prostate Cancer
Check if I qualifyExtracted eligibility criteria
Cancer type
Prostate Cancer
Disease stage
Required: Stage CLINICALLY LOCALIZED, T3A OR GREATER (NCCN)
Grade: ISUP grade group 4ISUP grade group 5 (ISUP)
newly diagnosed, biopsy-proven, clinically localized prostate adenocarcinoma; high-risk disease as defined by the NCCN guidelines (version 1.2023): Overall ISUP grade group 4 or 5, Clinical category T3a or greater, Serum PSA level greater than 20 ng/ml
Prior therapy
Cannot have received: any therapy for prostate cancer
The patient has received any therapy - be it radiation, surgical or drug therapy - for his prostate cancer.
Cannot have received: investigational agent
receiving any other investigational agent(s), or he has received any such agent(s) within the previous 30 days, or he is scheduled to receive any such agent(s) in the period up to the planned date for the last study visit.
Cannot have received: PSMA-avid PET imaging agent
previously undergone PET imaging with any PSMA-avid product
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify